STEM CELL
THERAPIES:
THE CHAL­LENGE

Diabetes Stem Cell Therapies:

The stem cell revolution is still to be realized.

THE PROMISE:

The cells work…

There have been major breakthroughs in stem cell therapies for Type 1 diabetes.

THE PROMISE:

The cells work…

There have been major breakthroughs in stem cells for Type 1 diabetes.

THE PROBLEM:

Current implant systems DON’T work

  • Technology to implant stem cells has lagged stem cell development.
  • Immunosuppression is still needed, so it’s not a “home run” treatment to reach all diabetes patients; Immunosuppression substantially limits patient’s lives and increases risk of illness.
  • Oxygenation support is missing from most encapsulation strategies. The pancreas’ insulin-producing cells are well vascularized and oxygenated—critical for their long-term functioning.
  • Gene editing and immune stealth approaches are years away and may still require encapsulation for safety.

In diabetes clinical trials there have been no major successes without immuno­suppression.

Lifelong immunosuppression greatly increases the risk of infections and cancer. As a result, patients may limit social contact. Very few patients are clinically eligible for cell therapy with immunosuppression and these immunosuppression drugs are costly at around $100K/year.

THE SOLUTION:

Persista Bio™ technology breaks through prior cell therapy roadblocks and enables implantable cell therapies—it avoids immune system rejection and supports the longterm health of the cells with oxygenation.

See our technology

Copyright© 2024. Persista Bio™ Inc. and O2Line™ are trademarks of Persista Bio™, Inc.